Synovial Targeting and Redox-Triggered Release: A Dual Strategy in Peptide-Drug Conjugates for Rheumatoid Arthritis

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Immunology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and destruction.
• Current treatments like sinomenine (SIN) face challenges with rapid clearance and systemic side effects.

Purpose of the Study:

• To develop optimized peptide-drug conjugates (PDCs) for targeted RA therapy.
• To enhance plasma stability and achieve selective drug release at the disease site.

Main Methods:

• Designed two synovial homing peptide-sinomenine conjugates (SIN-SS-DRL and dSIN-SS-DRL) using reduction-sensitive disulfide bonds.
• Evaluated in vitro suppression of pro-inflammatory cytokines.
• Assessed in vivo efficacy in adjuvant-induced arthritis mouse models.

Main Results:

• The new conjugates demonstrated improved plasma stability and selective, glutathione-triggered release of SIN.
• LC-MS confirmed accelerated and more complete drug release from the dual-disulfide conjugate.
• In vitro and in vivo studies showed significant reduction in joint inflammation and bone damage, with efficacy comparable to methotrexate.

Conclusions:

• Dual disulfide-linked PDCs represent a promising targeted therapy for RA.
• The conjugates integrate active synovial homing and passive redox-responsive release for superior therapeutic outcomes.
• These PDCs offer a potentially favorable safety profile for RA treatment.